PDF(Pubmed)
Abstract：
UNASSIGNED: No prior systematic review and meta-analysis has specifically verified the association of Mediterranean diet (MedDiet)-based interventions with biomarkers of cardiometabolic health in children and adolescents.
UNASSIGNED: To review and analyze the randomized clinical trials (RCTs) that assessed the effects of MedDiet-based interventions on biomarkers of cardiometabolic health among children and adolescents.
UNASSIGNED: Four electronic databases were searched (PubMed, Cochrane Library, Web of Science, and Scopus) from database inception to April 25, 2024.
UNASSIGNED: Only RCTs investigating the effect of interventions promoting the MedDiet on cardiometabolic biomarkers (ie, systolic blood pressure [SBP], diastolic blood pressure [DBP], triglycerides [TGs], total cholesterol [TC], high-density lipoprotein cholesterol [HDL-C], low-density lipoprotein cholesterol [LDL-C], glucose, insulin, and homeostatic model assessment for insulin resistance [HOMA-IR]) among children and adolescents (aged ≤18 years) were included.
UNASSIGNED: A systematic review and meta-analysis was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. Data were extracted from the studies by 2 independent reviewers. Results across studies were summarized using random-effects meta-analysis.
UNASSIGNED: The effect size of each trial was computed by unstandardized mean differences (MDs) of changes in biomarker levels (ie, SBP, DBP, TGs, TC, HDL-C, LDL-C, glucose, insulin, HOMA-IR) between the intervention and the control groups. The quality of the evidence was assessed using the Grading of Recommendations, Assessment, Development, and Evaluations approach.
UNASSIGNED: Nine RCTs were included (mean study duration, 17 weeks; range, 8-40 weeks). These studies involved 577 participants (mean age, 11 years [range, 3-18 years]; 344 girls [59.6%]). Compared with the control group, the MedDiet-based interventions showed a significant association with reductions in SBP (mean difference, -4.75 mm Hg; 95% CI, -8.97 to -0.52 mm Hg), TGs (mean difference, -16.42 mg/dL; 95% CI, -27.57 to -5.27 mg/dL), TC (mean difference, -9.06 mg/dL; 95% CI, -15.65 to -2.48 mg/dL), and LDL-C (mean difference, -10.48 mg/dL; 95% CI, -17.77 to -3.19 mg/dL) and increases in HDL-C (mean difference, 2.24 mg/dL; 95% CI, 0.34-4.14 mg/dL). No significant associations were observed with the other biomarkers studied (ie, DBP, glucose, insulin, and HOMA-IR).
UNASSIGNED: These findings suggest that MedDiet-based interventions may be useful tools to optimize cardiometabolic health among children and adolescents.
UNASSIGNED: To review and analyze the randomized clinical trials (RCTs) that assessed the effects of MedDiet-based interventions on biomarkers of cardiometabolic health among children and adolescents.
UNASSIGNED: Four electronic databases were searched (PubMed, Cochrane Library, Web of Science, and Scopus) from database inception to April 25, 2024.
UNASSIGNED: Only RCTs investigating the effect of interventions promoting the MedDiet on cardiometabolic biomarkers (ie, systolic blood pressure [SBP], diastolic blood pressure [DBP], triglycerides [TGs], total cholesterol [TC], high-density lipoprotein cholesterol [HDL-C], low-density lipoprotein cholesterol [LDL-C], glucose, insulin, and homeostatic model assessment for insulin resistance [HOMA-IR]) among children and adolescents (aged ≤18 years) were included.
UNASSIGNED: A systematic review and meta-analysis was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. Data were extracted from the studies by 2 independent reviewers. Results across studies were summarized using random-effects meta-analysis.
UNASSIGNED: The effect size of each trial was computed by unstandardized mean differences (MDs) of changes in biomarker levels (ie, SBP, DBP, TGs, TC, HDL-C, LDL-C, glucose, insulin, HOMA-IR) between the intervention and the control groups. The quality of the evidence was assessed using the Grading of Recommendations, Assessment, Development, and Evaluations approach.
UNASSIGNED: Nine RCTs were included (mean study duration, 17 weeks; range, 8-40 weeks). These studies involved 577 participants (mean age, 11 years [range, 3-18 years]; 344 girls [59.6%]). Compared with the control group, the MedDiet-based interventions showed a significant association with reductions in SBP (mean difference, -4.75 mm Hg; 95% CI, -8.97 to -0.52 mm Hg), TGs (mean difference, -16.42 mg/dL; 95% CI, -27.57 to -5.27 mg/dL), TC (mean difference, -9.06 mg/dL; 95% CI, -15.65 to -2.48 mg/dL), and LDL-C (mean difference, -10.48 mg/dL; 95% CI, -17.77 to -3.19 mg/dL) and increases in HDL-C (mean difference, 2.24 mg/dL; 95% CI, 0.34-4.14 mg/dL). No significant associations were observed with the other biomarkers studied (ie, DBP, glucose, insulin, and HOMA-IR).
UNASSIGNED: These findings suggest that MedDiet-based interventions may be useful tools to optimize cardiometabolic health among children and adolescents.
摘要：
■之前没有系统评价和荟萃分析特别验证了基于地中海饮食（MedDiet）的干预措施与儿童和青少年心脏代谢健康生物标志物的关联。
回顾和分析评估基于MedDiet的干预措施对儿童和青少年心脏代谢健康生物标志物影响的随机临床试验（RCT）。
■搜索了四个电子数据库(PubMed，科克伦图书馆,WebofScience,和Scopus）从数据库开始到2024年4月25日。
■仅RCT调查干预措施促进MedDiet对心脏代谢生物标志物的影响（即，收缩压[SBP]，舒张压[DBP]，甘油三酯[TG]，总胆固醇[TC]，高密度脂蛋白胆固醇[HDL-C]，低密度脂蛋白胆固醇[LDL-C]，葡萄糖，胰岛素，包括儿童和青少年（≤18岁）的胰岛素抵抗的稳态模型评估[HOMA-IR]）。
■在系统评价和荟萃分析声明的首选报告项目之后，进行了系统评价和荟萃分析。数据由2名独立审稿人从研究中提取。使用随机效应荟萃分析总结了所有研究的结果。
■每个试验的效应大小是通过生物标志物水平变化的非标准化平均差异（MD）计算的（即，SBP,DBP,TG,TC,HDL-C,LDL-C,葡萄糖，胰岛素，HOMA-IR)在干预组和对照组之间。使用建议分级评估证据的质量，评估,发展,和评估方法。
■纳入了9个随机对照试验(平均研究时间，17周；范围，8-40周）。这些研究涉及577名参与者(平均年龄，11年[范围，3-18岁]；344名女孩[59.6%]）。与对照组相比,基于MedDiet的干预措施显示出与SBP降低显著相关(平均差异，-4.75mmHg；95%CI，-8.97至-0.52mmHg），TG(平均差，-16.42mg/dL；95%CI，-27.57至-5.27mg/dL），TC(平均差，-9.06mg/dL；95%CI，-15.65至-2.48mg/dL），和LDL-C(平均差，-10.48mg/dL；95%CI，-17.77至-3.19mg/dL）和HDL-C增加（平均差异，2.24mg/dL；95%CI，0.34-4.14mg/dL）。与其他研究的生物标志物没有观察到显著的关联(即，DBP,葡萄糖，胰岛素，和HOMA-IR）。
这些研究结果表明，基于MedDiet的干预措施可能是优化儿童和青少年心脏代谢健康的有用工具。
回顾和分析评估基于MedDiet的干预措施对儿童和青少年心脏代谢健康生物标志物影响的随机临床试验（RCT）。
■搜索了四个电子数据库(PubMed，科克伦图书馆,WebofScience,和Scopus）从数据库开始到2024年4月25日。
■仅RCT调查干预措施促进MedDiet对心脏代谢生物标志物的影响（即，收缩压[SBP]，舒张压[DBP]，甘油三酯[TG]，总胆固醇[TC]，高密度脂蛋白胆固醇[HDL-C]，低密度脂蛋白胆固醇[LDL-C]，葡萄糖，胰岛素，包括儿童和青少年（≤18岁）的胰岛素抵抗的稳态模型评估[HOMA-IR]）。
■在系统评价和荟萃分析声明的首选报告项目之后，进行了系统评价和荟萃分析。数据由2名独立审稿人从研究中提取。使用随机效应荟萃分析总结了所有研究的结果。
■每个试验的效应大小是通过生物标志物水平变化的非标准化平均差异（MD）计算的（即，SBP,DBP,TG,TC,HDL-C,LDL-C,葡萄糖，胰岛素，HOMA-IR)在干预组和对照组之间。使用建议分级评估证据的质量，评估,发展,和评估方法。
■纳入了9个随机对照试验(平均研究时间，17周；范围，8-40周）。这些研究涉及577名参与者(平均年龄，11年[范围，3-18岁]；344名女孩[59.6%]）。与对照组相比,基于MedDiet的干预措施显示出与SBP降低显著相关(平均差异，-4.75mmHg；95%CI，-8.97至-0.52mmHg），TG(平均差，-16.42mg/dL；95%CI，-27.57至-5.27mg/dL），TC(平均差，-9.06mg/dL；95%CI，-15.65至-2.48mg/dL），和LDL-C(平均差，-10.48mg/dL；95%CI，-17.77至-3.19mg/dL）和HDL-C增加（平均差异，2.24mg/dL；95%CI，0.34-4.14mg/dL）。与其他研究的生物标志物没有观察到显著的关联(即，DBP,葡萄糖，胰岛素，和HOMA-IR）。
这些研究结果表明，基于MedDiet的干预措施可能是优化儿童和青少年心脏代谢健康的有用工具。
